Home » today » Business » Akulaku Jack Ma Enters, Injects Capital into Neo Bank IDR 2.5 T

Akulaku Jack Ma Enters, Injects Capital into Neo Bank IDR 2.5 T

Jakarta, CNBC Indonesia – PT Bank Neo Commerce Tbk (BBYB) plans to increase capital through a rights issue scheme with a target of Rp 2.5 trillion in funds raised.

President Director of Bank Neo Commerce Tjandra Gunawan said this corporate action had obtained shareholder approval at the EGMS which was held on May 28, 2021.

“Rights issue is currently underway, our target [bisa menghimpun dana] Pre-emptive rights of Rp 2.5 trillion,” said Tjandra in a public presentation, Monday (6/9/2021).

With the rights issue, the company will increase its core capital to Rp 3 trillion by the end of this year and has met the minimum bank capital requirements by the Financial Services Authority by the end of December 2022.

“Our target is to book Rp 3 trillion, it will fulfill this year. Not only complying with OJK regulations, but also being part of our plan to transform into a digital bank,” said Tjandra.

As previously stated, the bank codenamed BBYB will use the proceeds from the rights issue to be used for capital expenditures and increase core capital. The rest is for investment in the technology and information (IT) sector and operational spending.

“We have a capital plan, we will carry out a rights issue, now we are in the PUT process, the injection is to pursue a capital of Rp 2 trillion this year,” said Tjandra Gunawan, in an interview session with the media crew, Wednesday (28/4/2021).

For information, until last July 29, Akulaku, the fintech lending injected by Ant Financial, became the company’s controlling shareholder.

He said that this change in controller is expected to have a positive impact on BBYB. However, said Tjandra, his party is always open to cooperating not only with the Akulaku ecosystem.

“With Akulaku there will be synergy, we make that something that becomes our starting point,” he said.

[Gambas:Video CNBC]

(hps / hps)



– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.